Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

FEBUXOSTAT

Inhibitor of xanthine oxidase

ONCOLOGY

CURRENT DEVELOPMENT PHASE: tumour lysis syndrome

preclinicl
phase i
phase ii
phase iii
pre-registration
post-registration

Febuxostat (ADENURIC®) is a potent, non-purine selective inhibitor of xanthine oxidase (XO), indicated for the treatment of hyperuricaemia (excess of uric acid) in patients suffering from gout and in adult patients at risk of tumour lysis syndrome.

This second indication was approved based on the success of the FLORENCE study, which enrolled 347 patients with lymphoma and leukemia, in 79 highly specialized centers for the treatment of hematological tumours. In this study Febuxostat, compared to the standard of care, showed a significant superiority in the control of uricaemia in intermediate/high risk adult patients with tumor lysis syndrome.

VISIT OUR CLINICAL TRIALS DATABASE


THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more